Method of preparing oligomeric compounds using modified coupling protocols
US-2015368288-A1 · Dec 24, 2015 · US
US9879043B1 · US · B1
| Field | Value |
|---|---|
| Publication number | US-9879043-B1 |
| Application number | US-201414298874-A |
| Country | US |
| Kind code | B1 |
| Filing date | Jun 6, 2014 |
| Priority date | Jun 6, 2013 |
| Publication date | Jan 30, 2018 |
| Grant date | Jan 30, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present disclosure relates to the synthesis of non-natural analogs of S-adenosyl-L-methionine (SAM) and/or of Se-adenosyl-L-methionine (SeAM) by reacting a methionine analog and adenosine triphosphate (ATP) in the presence of at least one methionine adenosyltransferase (MAT), and to use thereof with downstream SAM and/or SeAM utilizing enzymes. The non-natural analogs of SAM and/or SeAM have the general formula: where X is S or Se, and R 1 is an alkyl group.
Opening claim text (preview).
What is claimed is: 1. An S-adenosyl-L-methionine (SAM) or Se-adenosyl-L-methionine (SeAM) analog of the Formula III: wherein X is selected from the group consisting of S and Se; wherein, when X is S, R 1 is selected from the group consisting of: wherein, when X is Se, R 1 is selected from the group consisting of: 2. A compound of the Formula II: wherein R 1 is selected from the group consisting of and X is S. 3. An S-adenosyl-L-methionine analog of the Formula III: wherein X is S and R 1 is selected from the group consisting of: 4. An S-adenosyl-L-methionine (SAM) analog of the formula: 5. A method of producing an S-adenosyl-L-methionine analog according to claim 4 , comprising the step of reacting a first substrate comprising methionine-tetrazole with a second substrate comprising adenosine triphosphate (ATP) in the presence of a methionine adenosyltransferase (MAT). 6. The method of claim 5 , wherein the MAT comprises at least one of human MAT II catalytic alpha and regulatory beta subunit (hMAT2), human MAT II catalytic alpha subunit alone (hMAT2A), human MAT I catalytic subunit alpha (hMAT1A), Escherichia coli MAT (eMAT), Sulfolobus solfataricus MAT (sMAT), and Methanocaldococcus jannaschii MAT (mMAT). 7. A method of producing the S-adenosyl-L-methionine analog of claim 1 , comprising the step of reacting a first substrate comprising a methionine analog with a second substrate comprising adenosine triphosphate (ATP) in the presence of a methionine adenosyltransferase (MAT). 8. The method of claim 7 , wherein the MAT comprises at least one of human MAT II catalytic alpha and regulatory beta subunit (hMAT2), human MAT II catalytic alpha subunit alone (hMAT2A), human MAT I catalytic subunit alpha (hMAT1A), Escherichia coli MAT (eMAT), Sulfolobus solfataricus MAT (sMAT), and Methanocaldococcus jannaschii MAT (mMAT). 9. The method of claim 7 , wherein the first substrate is of the Formula II: wherein R 1 is selected from the group consisting of wherein X is S. 10. A method of producing the Se-adenosyl-L-methionine analog of claim 1 , comprising the step of reacting a first substrate comprising a methionine analog with a second substrate comprising adenosine triphosphate (ATP) in the presence of a methionine adenosyltransferase (MAT). 11. The method of claim 10 , wherein the first substrate is of the Formula II: wherein R 1 is selected from the group consisting of wherein X is Se. 12. A method of producing an indolocarbazole analog, comprising the step of reacting a first substrate comprising a methionine analog with a second substrate in the presence of a methionine adenosyltransferase (MAT), wherein the methionine analog is of the Formula II: wherein R 1 is selected from the group consisting of wherein X is selected from the group consisting of S and Se; and wherein the second substrate comprises at least one indolocarbazole group. 13. The method of claim 12 , wherein the MAT comprises at least one of human MAT II catalytic alpha and regulatory beta subunit (hMAT2), human MAT II catalytic alpha subunit alone (hMAT2A), human MAT I catalytic subunit alpha (hMAT1A), Escherichia coli MAT (eMAT), Sulfolobus solfataricus MAT (sMAT), and Methanocaldococcus jannaschii MAT (mMAT).
Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms (ergot-alcaloids C12P17/183) · CPC title
having a condensed ring system containing a six-membered ring having two nitrogen atoms in the same ring, e.g. purine nucleosides · CPC title
Purine radicals · CPC title
containing three or more hetero rings · CPC title
of an acyclic saturated carbon skeleton · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.